barry quart  ardea biosciences  inc  zoominfocom   insider trading  quart barry d  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  quart barry d select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm heron therapeutics inc hrtx quart barry dchief executive officerdirector    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view other  am nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  pm nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  pm na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view option award  pm na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  am na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view other  pm nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  pm nana heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view exercise  pm na heron therapeutics inc hrtx quart barry dchief executive officerdirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view disposition  am na synageva biopharma corp geva quart barry ddirector   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  barry d quart  encinitas ca  intelius sign in we found barry d quart in encinitas ca barry d quart intelius found that barry d quart is a male between  and  years old from encinitas ca we have connected them to  addresses  phones and  relatives or associates also known as barry david quart get report now age barry d quart is in his s barry has lived in encinitas ca las vegas nv evansville in barrys relatives kelly quart kristine quart gabrielle quart barry d quart zodiac signcapricorn gendermale professional status ardea biosciences  inc get report now want to know more about barry get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about barry or use our people search engine to find others get background check on barry d quart get a criminal check on barry d quart get a public record report on barry d quart get a people search report on barry d quart barry d quarts contact information known cities lived in find out where barry d quart has lived as well as barry d quarts phone numbers and email addresses barry d quart has lived in  states california address for barry d quart  v r encinitas ca has lived in encinitas ca las vegas nv get full address report phone numbers associated with barry d quart    encinitas ca    encinitas ca    encinitas ca get full phone report email addresses associated with barry d quart bcom ktcom ktcom get email report barry d quarts education information known schools attended learn about barry d quarts academic history find out which schools barry d quart attended the dates attended as well as the degrees barry d quart received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act barry d quart has attended  school grant high school  –  barry d quarts professional information information regarding barry d quarts professional history find out previous places barry d quart has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act barry d quart has worked at  places company ardea biosciences  inc company trimeris  inc barry d quarts experience title company ardea biosciences  inc job details title company trimeris  inc job details additional professional information on barry d quart see barry d quarts linkedin profile barry d quarts social network and potential email matches find out potential social network profiles and potential email usernamed for barry d quart barry d quarts known social networks and potential email matches find all of barry d quarts social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches barry quart username matches barryquart quartbarry barryquart quartbarry barryquart quartbarry barryquart quartbarry bquart popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches b quart intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here barry d quart pharmd executive profile  biography  bloomberg july    am et biotechnology company overview of heron therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile barry d quart pharmdchief executive officer  director heron therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr barry d quart pharmd has been the chief executive officer of heron therapeutics inc since may   dr quart serves as the scientific advisor of napo pharmaceuticals inc he served as the chief executive officer and president at ardea biosciences inc since december   which was acquired by astrazeneca plc in june  he served as general manager for americas region kodaks business solutions and services of eastman kodak co he served as  the president of napo pharmaceuticals inc from june  to july   and served as its chief scientific officer until july   he served as the president and chief executive officer of intrabiotics pharmaceuticals inc since december   he served as senior vice president of pfizer global research and development he served as senior vice president and head of drug development for agouron pharmaceuticals inc a division of the warnerlambert company since  and also served as its president of research and development since  where he was instrumental in the development and registration of viracept which went from the lab bench to nda approval in  months dr quart served as vice president of regulatory affairs for agouron pharmaceuticals inc since joining in  he served as an executive director of international regulatory affairs for bristolmyers squibb company since  dr quart served with bristolmyers squibb for ten years experience in both clinical research and regulatory affairs where he was actively involved in the development and registration of nine important drugs including paclitaxel didanosine stavudine and sotalol within the newly created pfizer global research and development division he served as senior vice president of la jolla laboratories he serves as a director of neurogenetic pharmaceuticals inc he has been a director of ardea biosciences inc since december   heron therapeutics inc since june  dr quart served as a director of trimeris inc since june  and director of synageva bio pharma corp from june  to june   he served as a director of napo pharmaceuticals inc from may   to july   he served as an executive director of intrabiotics pharmaceuticals inc since december   he served as a director of the la jolla laboratories dr quart received a pharmd in clinical pharmacy from the university of california san franciscoread full background corporate headquarters  campus point courtsan diego california united statesphone fax  board members memberships directorneurogenetic pharmaceuticals incpresentdirectorardea biosciences incpresentchief executive officer  directorheron therapeutics inc education doctorate university of californiasan francisco other affiliations agouron pharmaceuticals incsynageva biopharma corpintrabiotics pharmaceuticals inctrimeris inceastman kodak companyuniversity of californiasan francisconapo pharmaceuticals incardea biosciences incneurogenetic pharmaceuticals inc annual compensation salarytotal annual compensation stocks options all other compensationexercised optionsexercised options valueexercisable optionsexercisable options valueunexercisable optionsunexercisable options valuetotal value of optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact heron therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close barry d quart pharmd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in barry d quart pharmd dir chief executive officer principal financial officer and principal accounting officer at heron therapeutics inc view full profile are you barry d quart pharmd claim your profile   sign up for equilar atlas and view barry d quart pharmds full profile with equilar atlas you can identify corporate executives in barry d quart pharmds network and community follow changes in barry d quart pharmds employment and moneyinmotion connect with barry d quart pharmd through your network of contacts barry d quart pharmds executive work history current dir chief executive officer principal financial officer and principal accounting officer heron therapeutics inc past to view barry d quart pharmds complete executive work history sign up now age      barry d quart pharmds biography barry d quart pharmd has served as a director of heron since june  dr quart was appointed chief executive officer of the company in may  dr quart has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products in  dr quart cofounded ardea biosciences inc and served as its president and chief executive officer from its inception through may  and as a director through its acquisition by astrazeneca plc in june  previously he was with pfizer inc as senior vice president of pfizer global research and developme  read more barry d quart pharmd has served as a director of heron since june  dr quart was appointed chief executive officer of the company in may  dr quart has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products in  dr quart cofounded ardea biosciences inc and served as its president and chief executive officer from its inception through may  and as a director through its acquisition by astrazeneca plc in june  previously he was with pfizer inc as senior vice president of pfizer global research and development and the director of pfizers la jolla laboratories prior to pfizers acquisition of the warnerlambert company dr quart was president of research and development at agouron pharmaceuticals inc a division of the warnerlambert company dr quart joined agouron in  and was instrumental in the development and registration of viracept® nelfinavir dr quart also served as a director of synageva biopharma corp from june  through its acquisition by alexion pharmaceuticals inc in june  dr quart received a pharmd degree from the university of california san francisco dr quarts qualifications to serve on our board include his experience in senior management and as a director with other biotechnology and pharmaceutical companies and his prior drug development experience source heron therapeutics inc on    sign up for equilar atlas and view barry d quart pharmds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like barry d quart pharmd more specifically youll be able to identify corporate executives in barry d quart pharmds network and community follow changes in barry d quart pharmds employment and moneyinmotion connect with barry d quart pharmd through your network of conections view full profile   search for over  executive profiles bio example barry d quart pharmd barry d quart pharmds connections  sign up now to view barry d quart pharmds  connections » srinivas akkaraju board member seattle genetics inc david t hagerty executive vice president clinical development conatus pharmaceuticals inc henry j fuchs president worldwide research and development biomarin pharmaceutical inc stephen r davis dir president and chief executive officer acadia pharmaceuticals inc mark a goldberg board member immunogen inc brian g drazba former vice president finance and chief financial officer heron therapeutics inc kimberly j manhard executive vice president drug development heron therapeutics inc wendy l dixon board member incyte corporation john b whelan former president chief executive officer and chief financial officer heron therapeutics inc kevin c tang chairman of the board heron therapeutics inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft   hrtx barry d quart insider trades for heron therapeutics inc bulletin merck profit and sales top expectations amid big jump in keytruda sales » investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close heron therapeutics inc nasdaq hrtx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus heron therapeutics inc after hours  quotes are delayed by  min jul    pm hrtx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual barry d quart dr barry d quart is chief executive officer  director at heron therapeutics inc he is on the board of directors at heron therapeutics inc and neurogenetic pharmaceuticals inc dr quart was previously employed as independent director by synageva biopharma corp president chief executive officer  director by ardea biosciences inc president by ps pharmaceuticals inc presidentresearch  development by agouron pharmaceuticals inc director svpglobal research  development by pfizer la jolla and senior vice president by pfizer global research  development he also served on the board at trimeris inc he received his doctorate degree from the university of california san francisco transactions date shares transaction value     derivativenonderivative trans at  per share           derivativenonderivative trans at  per share      gift at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share           disposition at  per share      gift at  per share      gift at  per share           acquisition at  per share      acquisition at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr kevin c tang chairman mr robert h rosen president director  chief commercial officer dr barry d quart chief executive officer  director mr robert e hoffman chief financial officer  senior vpfinance dr thomas b ottoboni svppharmaceutical research  development ms kimberly j manhard executive vice presidentdrug development mr christian waage director mr daniel martin vice presidentmarketing mr david l szekeres secretary senior vp general counsel  ir contact mr sean t ristine vice presidenthuman resources mr john w poyhonen independent director mr craig a johnson independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest acan snap fall even more as lockups expire achip stocks are cool again but reality is here awhere to get chipotle queso check out this interactive map aaarons acquires its largest franchisee in allcash deal aexpedia stock price target raised to  from  at piper jaffray aa provocative new analysis suggests you don’t have to take all your antibiotics after all aa case for buying the freakin’ dip with amazon as the mooch might now say apriceline stock price target raised to  from  at piper jaffray asjw group upgraded to buy from neutral at janney avf corp stock price target raised to  from  at susquehanna financial adollar spins wheels ahead of gdp report expected to show faster clip of growth avf corp upgraded to positive from neutral at susquehanna financial ateradyne upgraded to overweight from sector weight at keybanc capital alogmein upgraded to overweight from sector weight at keybanc capital atwitter stock price target raised to  from  at rbc capital acocacola zero sugar sparks analyst optimism but other factors could stifle growth aintel stock price target raised to  from  at suntrust rh amastercard stock price target raised to  from  at suntrust rh acharter communications stock price target raised to  from  at suntrust rh awhy the gdp report may show us economy growing twice as fast loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  board of directors  heron therapeutics skip to main content search form home about heron board of directors menu home about heroncompany overview grants sponsorships and charitable giving management board of directors compliance contact us careers our focus product portfolio patient​investigator resources investor resources board of directors kevin c tangchairman barry d quart pharmdchief executive officer and director robert h rosenpresident and director craig a johnsondirector john w poyhonendirector christian waagedirector kevin c tangchairman kevin c tang has served as director of heron since february  and as chairman since july  mr tang has more than  years of experience evaluating creating and building biotechnology companies that are focused on developing treatments for lifethreatening and debilitating diseases and conditions mr tang is the president of tang capital management llc a life sciencesfocused investment company he founded in  from  to  mr tang held various positions at deutsche banc alex brown inc an investment banking firm most recently serving as managing director and head of the firms life sciences research group since august  mr tang has served as a director and the chairman of la jolla pharmaceutical company in  mr tang cofounded ardea biosciences inc and served as a director from inception through its acquisition by astrazeneca plc in june  from  through its acquisition by endo pharmaceuticals inc in  he served as a director of penwest pharmaceuticals co from  to  he was a director of trimeris inc acquired by synageva biopharma corp mr tang received a bs degree from duke university back to top barry d quart pharmdchief executive officer and director barry d quart pharmd has served as a director of heron since june  dr quart was appointed chief executive officer of the company in may  dr quart has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products in  dr quart cofounded ardea biosciences inc and served as its president and chief executive officer from its inception through may  and as a director through its acquisition by astrazeneca plc in june  previously he was with pfizer inc as senior vice president of pfizer global research and development and the director of pfizers la jolla laboratories prior to pfizers acquisition of the warnerlambert company dr quart was president of research and development at agouron pharmaceuticals inc a division of the warnerlambert company dr quart joined agouron in  and was instrumental in the development and registration of viracept® nelfinavir dr quart also served as a director of synageva biopharma corp from june  through its acquisition by alexion pharmaceuticals inc in june  dr quart received a pharmd degree from the university of california san francisco back to top robert h rosenpresident and director robert h rosen has served as a director of heron since july  mr rosen was appointed president in may  and prior to that served as our senior vice president and chief commercial officer since october  mr rosen has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing pharmaceutical products from march  to october  mr rosen served as managing partner of scotia nordic llc a life sciences advisory firm from april  to march  mr rosen served as senior vice president of global commercial operations at dendreon corporation from  to  he served as global head of oncology at bayer healthcare pharmaceuticals where he was responsible for the development of the oncology business unit for regions that included the americas europe japan and asia pacific during his tenure at bayer mr rosen led the launch of nexavar®sorafenib for the treatment of renal cell carcinoma and hepatocellular carcinoma from  to  mr rosen was vice president of the oncology business unit at sanofisynthèlabo inc where he was responsible for the development of sanofis us oncology business and the launch of eloxatin® oxaliplatin for colon cancer mr rosen has been a director of la jolla pharmaceutical company since july  from november  to december  mr rosen served as a director of conkwest inc now nantkwest inc mr rosen received a bs degree in pharmacy from northeastern university back to top craig a johnsondirector craig a johnson has served as a director of heron since january  mr johnson has more than  years of experience serving in senior financial management roles and governing corporations primarily in the biotechnology industry since  mr johnson has served as a director of mirati therapeutics inc and la jolla pharmaceutical company since  mr johnson has served as a director of genomedx biosciences inc mr johnson served as a director of ardea biosciences inc from  through its acquisition by astrazeneca plc in june  from  to  mr johnson served as a director of adamis pharmaceuticals corporation from  to  he was chief financial officer of pure bioscience inc from  to  mr johnson was senior vice president and chief financial officer of novadel pharma inc mr johnson served as vice president and chief financial officer of torreypines therapeutics inc from  through its acquisition by raptor pharmaceuticals corp in  and then as vice president of a whollyowned subsidiary of raptor pharmaceutical corp from  to  from  to  mr johnson held various positions at mitokor inc most recently as chief financial officer and senior vice president of operations prior to  mr johnson held senior financial positions with several earlystage technology companies and also practiced as a certified public accountant with price waterhouse mr johnson received a bba degree in accounting from the university of michigandearborn back to top john w poyhonendirector john w poyhonen has served as a director of heron since january  mr poyhonen has more than  years of experience serving in leadership positions in biotechnology pharmaceutical and food ingredient companies and commercializing innovative products mr poyhonen is currently the president chief executive officer and a director of senomyx inc he joined senomyx in  as vice president and chief business officer was promoted in  to vice president and chief financial and business officer was named senior vice president chief financial and business officer in  was promoted to president and chief operating officer in  and promoted to his current role in january  from  to  mr poyhonen served in various sales and marketing positions for agouron pharmaceuticals inc most recently as vice president of national sales prior to holding this position mr poyhonen served as vice president of marketing and vice president of national accounts he was previously a director of ardea biosciences inc from  through its acquisition by astrazeneca plc in june  mr poyhonen received a ba degree in marketing from michigan state university and a mba degree from the university of kansas back to top christian waagedirector christian waage has served as a director of heron since june  mr waage has more than  years of regulatory legal and financial transaction experience primarily in the biotechnology industry mr waage currently serves as managing director at receptos a wholly owned subsidiary of celgene corporation mr waage joined receptos in december  as senior vice president and general counsel and played an instrumental role in its acquisition by celgene for b in august  prior to receptos he served as vice president general counsel and corporate secretary at websense inc from july  until its acquisition by vista equity partners for b in august  in addition to overseeing its acquisition his responsibilities at websense included all legal affairs including sec reporting and compliance corporate governance litigation and licensing operations prior to websense mr waage served as vice president general counsel and corporate secretary of ardea biosciences inc from march  until its acquisition by astrazeneca plc for b in july  prior to ardea biosciences mr waage practiced law for over a decade at dla piper where he was a partner mr waage received a jd from the university of san diego school of law and a ba degree in economics from the university of california san diego back to top home about heron our focus product portfolio patient​investigator resources investor resources site map terms of use privacy statement careers   heron therapeutics inc all rights reserved management  heron therapeutics skip to main content search form home about heron management menu home about heroncompany overview grants sponsorships and charitable giving management board of directors compliance contact us careers our focus product portfolio patient​investigator resources investor resources management barry d quart pharmdchief executive officer and director robert h rosenpresident and director robert e hoffmanchief financial officer and senior vp finance kimberly j manhardexecutive vp drug development thomas b ottoboni phdsenior vp pharmaceutical and preclinical research and development david l szekeressenior vp general counsel business development and corporate secretary sean t ristinevp human resources barry d quart pharmdchief executive officer and director barry d quart pharmd has served as a director of heron since june  dr quart was appointed chief executive officer of the company in may  dr quart has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products in  dr quart cofounded ardea biosciences inc and served as its president and chief executive officer from its inception through may  and as a director through its acquisition by astrazeneca plc in june  previously he was with pfizer inc as senior vice president of pfizer global research and development and the director of pfizers la jolla laboratories prior to pfizers acquisition of the warnerlambert company dr quart was president of research and development at agouron pharmaceuticals inc a division of the warnerlambert company dr quart joined agouron in  and was instrumental in the development and registration of viracept® nelfinavir dr quart also served as a director of synageva biopharma corp from june  through its acquisition by alexion pharmaceuticals inc in june  dr quart received a pharmd degree from the university of california san francisco back to top robert h rosenpresident and director robert h rosen has served as a director of heron since july  mr rosen was appointed president in may  and prior to that served as our senior vice president and chief commercial officer since october  mr rosen has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing pharmaceutical products from march  to october  mr rosen served as managing partner of scotia nordic llc a life science advisory firm from april  to march  mr rosen served as senior vice president of global commercial operations at dendreon corporation from  to  he served as global head of oncology at bayer healthcare pharmaceuticals where he was responsible for the development of the oncology business unit for regions that included the americas europe japan and asia pacific during his tenure at bayer mr rosen led the launch of nexavar® sorafenib for the treatment of renal cell carcinoma and hepatocellular carcinoma from  to  mr rosen was vice president of the oncology business unit at sanofisynthèlabo inc where he was responsible for the development of sanofis us oncology business and the launch of eloxatin® oxaliplatin for colon cancer mr rosen has been a director of la jolla pharmaceutical company since july  from november  to december  mr rosen served as a director of conkwest inc now nantkwest inc mr rosen received a bs degree in pharmacy from northeastern university back to top robert e hoffmanchief financial officer and senior vp finance robert e hoffman joined us as chief financial officer and senior vice president finance in april  prior to joining heron mr hoffman served as executive vice president and chief financial officer of innovus pharmaceuticals inc a biopharmaceutical company since september  prior to innovus pharmaceuticals inc mr hoffman was chief financial officer of anaptysbio inc a biopharmaceutical company from july  until september  he was part of the founding management team of arena pharmaceuticals inc in  a biopharmaceutical company ultimately serving as senior vice president finance and chief financial officer until march  and then again from august  until july  from march  to august  he served as chief financial officer for polaris group a biopharmaceutical company mr hoffman is a member of the board of directors of combimatrix corporation a molecular diagnostics company kura oncology inc a biopharmaceutical company and mabvax therapeutics holdings inc a biopharmaceutical company he also is a member of the financial accounting standards board’s small business advisory committee and is a member of the steering committee of the association of bioscience financial officers mr hoffman received his bba from st bonaventure university and is licensed as a cpa inactive in the state of california back to top kimberly j manhardexecutive vp drug development kimberly j manhard joined us as executive vice president drug development in january  ms manhard served as a director of heron from january  until she joined the management team ms manhard has more than  years of experience in drug development regulatory affairs and pharmaceutical operations from may  to january  ms manhard served as the senior vice president of regulatory affairs and development operations at ardea biosciences inc a whollyowned subsidiary of astrazeneca plc in her role at ardea ms manhard was instrumental in the development and december  regulatory approval of zurampic® lesinurad for the treatment of hyperuricemia associated with gout prior to joining ardea in  ms manhard was president of her own consultancy firm vice president of regulatory affairs for exelixis inc and held multiple regulatory positions at agouron pharmaceuticals inc a division of the warnerlambert company supporting development and commercialization of anticancer and antiviral products including viracept® nelfinavir she was also previously with bristol myers squibb company in regulatory affairs responsible for oncology compounds including taxol® paclitaxel and infectious disease compounds including videx® didanosine and zerit® stavudine ms manhard began her industry career in clinical research with eli lilly and company and gh besselaar associates covance inc ms manhard recieved a bs degree in zoology and a ba degree in french from the university of florida back to top thomas b ottoboni phdsenior vp pharmaceutical and preclinical research and development thomas b ottoboni phd joined us as vice president of pharmaceutical development in march  and was promoted to senior vice president of pharmaceutical and preclinical research and development in july  dr ottoboni has more than  years of drug development experience from  until  dr ottoboni was vice president of research and development at talima therapeutics inc where he worked on the develpment of a drug delivery implant to treat onychomycosis from  to  dr ottoboni served as executive vice president of strategy and operations at point biomedical corp where he developed several imaging and drug delivery systems from may  through july  dr ottoboni served as manager of systems development and drug delivery research for insite vision inc where he developed ophthalmic pharmaceutical delivery systems he previously served as director of drug delivery at vitaphore corp dr ottoboni is an inventor on more than  us patents in organic and macromolecular chemistry he received a bs degree in chemistry and a phd in organic chemistry from the university of california berkeley back to top david l szekeressenior vp general counsel business development and corporate secretary david l szekeres joined us as senior vice president general counsel business development and corporate secretary in march  mr szekeres has more than  years of legal and industry experience from february  to december  mr szekeres served as general counsel chief business officer principal financial officer and corporate secretary at regulus therapeutics inc in that role mr szekeres played a critical role in overseeing the company’s business financial and legal responsibilities as it developed into a clinicalstage corporation from  through its acquisition by thermo fisher scientific inc in  mr szekeres served as deputy general counsel chief mergers and acquisitions counsel and assistant corporate secretary at life technologies corporation from  to  mr szekeres served as corporate attorney at a number of law firms including o’melveny  myers llp and latham  watkins llp prior to  mr szekeres served as senior associate in investment banking at investment bank robertson stephens mr szekeres received a ba degree from the university of california irvine and a jd degree from duke university school of law back to top sean t ristine vp human resources sean t ristine joined us as senior director of human resources in august  and was promoted to vice president of human resources in september  mr ristine has more than  years of experience in human resources and business leadership from september  to august  mr ristine held key human resources positions at cadence pharmaceuticals inc most recently as senior director of human resources and was instrumental in that function as cadence grew to a commercialstage company with over  employees located throughout the us from  through  mr ristine held human resources management roles of increasing responsibility at kyocera wireless corp including director of human resources and facilities prior to this from  to  mr ristine held positions at kyocera america inc including manager of human resources mr ristine received a bs degree in business and organization behavior from brigham young university and an mba degree with an emphasis in human resources management from san diego state university back to top home about heron our focus product portfolio patient​investigator resources investor resources site map terms of use privacy statement careers   heron therapeutics inc all rights reserved contact us  heron therapeutics skip to main content search form home about heron contact us menu home about heroncompany overview grants sponsorships and charitable giving management board of directors compliance contact us careers our focus product portfolio patient​investigator resources investor resources contact us contact information to report an adverse event or product complaint call heron email medinfoherontxcom general information heron infoherontxcom career inquiries jobsherontxcom corporate contact  business development bdherontxcom investor  media relations irherontxcom corporate offices redwood city office  saginaw driveredwood city ca  san diego office  campus point court suite san diego ca  jersey city office  hudson street suite jersey city nj  transfer agent inquiries related to stock and transfer requirements including lost stock certificates and changes of name or address should be directed to our transfer agent computershare  quality circle suite college station tx wwwcomputersharecominvestor home about heron our focus product portfolio patient​investigator resources investor resources site map terms of use privacy statement careers   heron therapeutics inc all rights reserved board of directors  heron therapeutics skip to main content search form home about heron board of directors menu home about heroncompany overview grants sponsorships and charitable giving management board of directors compliance contact us careers our focus product portfolio patient​investigator resources investor resources board of directors kevin c tangchairman barry d quart pharmdchief executive officer and director robert h rosenpresident and director craig a johnsondirector john w poyhonendirector christian waagedirector kevin c tangchairman kevin c tang has served as director of heron since february  and as chairman since july  mr tang has more than  years of experience evaluating creating and building biotechnology companies that are focused on developing treatments for lifethreatening and debilitating diseases and conditions mr tang is the president of tang capital management llc a life sciencesfocused investment company he founded in  from  to  mr tang held various positions at deutsche banc alex brown inc an investment banking firm most recently serving as managing director and head of the firms life sciences research group since august  mr tang has served as a director and the chairman of la jolla pharmaceutical company in  mr tang cofounded ardea biosciences inc and served as a director from inception through its acquisition by astrazeneca plc in june  from  through its acquisition by endo pharmaceuticals inc in  he served as a director of penwest pharmaceuticals co from  to  he was a director of trimeris inc acquired by synageva biopharma corp mr tang received a bs degree from duke university back to top barry d quart pharmdchief executive officer and director barry d quart pharmd has served as a director of heron since june  dr quart was appointed chief executive officer of the company in may  dr quart has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products in  dr quart cofounded ardea biosciences inc and served as its president and chief executive officer from its inception through may  and as a director through its acquisition by astrazeneca plc in june  previously he was with pfizer inc as senior vice president of pfizer global research and development and the director of pfizers la jolla laboratories prior to pfizers acquisition of the warnerlambert company dr quart was president of research and development at agouron pharmaceuticals inc a division of the warnerlambert company dr quart joined agouron in  and was instrumental in the development and registration of viracept® nelfinavir dr quart also served as a director of synageva biopharma corp from june  through its acquisition by alexion pharmaceuticals inc in june  dr quart received a pharmd degree from the university of california san francisco back to top robert h rosenpresident and director robert h rosen has served as a director of heron since july  mr rosen was appointed president in may  and prior to that served as our senior vice president and chief commercial officer since october  mr rosen has more than  years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing pharmaceutical products from march  to october  mr rosen served as managing partner of scotia nordic llc a life sciences advisory firm from april  to march  mr rosen served as senior vice president of global commercial operations at dendreon corporation from  to  he served as global head of oncology at bayer healthcare pharmaceuticals where he was responsible for the development of the oncology business unit for regions that included the americas europe japan and asia pacific during his tenure at bayer mr rosen led the launch of nexavar®sorafenib for the treatment of renal cell carcinoma and hepatocellular carcinoma from  to  mr rosen was vice president of the oncology business unit at sanofisynthèlabo inc where he was responsible for the development of sanofis us oncology business and the launch of eloxatin® oxaliplatin for colon cancer mr rosen has been a director of la jolla pharmaceutical company since july  from november  to december  mr rosen served as a director of conkwest inc now nantkwest inc mr rosen received a bs degree in pharmacy from northeastern university back to top craig a johnsondirector craig a johnson has served as a director of heron since january  mr johnson has more than  years of experience serving in senior financial management roles and governing corporations primarily in the biotechnology industry since  mr johnson has served as a director of mirati therapeutics inc and la jolla pharmaceutical company since  mr johnson has served as a director of genomedx biosciences inc mr johnson served as a director of ardea biosciences inc from  through its acquisition by astrazeneca plc in june  from  to  mr johnson served as a director of adamis pharmaceuticals corporation from  to  he was chief financial officer of pure bioscience inc from  to  mr johnson was senior vice president and chief financial officer of novadel pharma inc mr johnson served as vice president and chief financial officer of torreypines therapeutics inc from  through its acquisition by raptor pharmaceuticals corp in  and then as vice president of a whollyowned subsidiary of raptor pharmaceutical corp from  to  from  to  mr johnson held various positions at mitokor inc most recently as chief financial officer and senior vice president of operations prior to  mr johnson held senior financial positions with several earlystage technology companies and also practiced as a certified public accountant with price waterhouse mr johnson received a bba degree in accounting from the university of michigandearborn back to top john w poyhonendirector john w poyhonen has served as a director of heron since january  mr poyhonen has more than  years of experience serving in leadership positions in biotechnology pharmaceutical and food ingredient companies and commercializing innovative products mr poyhonen is currently the president chief executive officer and a director of senomyx inc he joined senomyx in  as vice president and chief business officer was promoted in  to vice president and chief financial and business officer was named senior vice president chief financial and business officer in  was promoted to president and chief operating officer in  and promoted to his current role in january  from  to  mr poyhonen served in various sales and marketing positions for agouron pharmaceuticals inc most recently as vice president of national sales prior to holding this position mr poyhonen served as vice president of marketing and vice president of national accounts he was previously a director of ardea biosciences inc from  through its acquisition by astrazeneca plc in june  mr poyhonen received a ba degree in marketing from michigan state university and a mba degree from the university of kansas back to top christian waagedirector christian waage has served as a director of heron since june  mr waage has more than  years of regulatory legal and financial transaction experience primarily in the biotechnology industry mr waage currently serves as managing director at receptos a wholly owned subsidiary of celgene corporation mr waage joined receptos in december  as senior vice president and general counsel and played an instrumental role in its acquisition by celgene for b in august  prior to receptos he served as vice president general counsel and corporate secretary at websense inc from july  until its acquisition by vista equity partners for b in august  in addition to overseeing its acquisition his responsibilities at websense included all legal affairs including sec reporting and compliance corporate governance litigation and licensing operations prior to websense mr waage served as vice president general counsel and corporate secretary of ardea biosciences inc from march  until its acquisition by astrazeneca plc for b in july  prior to ardea biosciences mr waage practiced law for over a decade at dla piper where he was a partner mr waage received a jd from the university of san diego school of law and a ba degree in economics from the university of california san diego back to top home about heron our focus product portfolio patient​investigator resources investor resources site map terms of use privacy statement careers   heron therapeutics inc all rights reserved